Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
|Articles|September 30, 2015
Aziz Nazha on Adverse Events Associated With Treatment for MDS
Author(s)Aziz Nazha
Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses adverse events associated with treatment for myelodysplastic syndrome (MDS).
Advertisement
Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses adverse events associated with treatment for myelodysplastic syndrome (MDS).
Advertisement
Related to this article
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Advertisement
Advertisement